DnB Asset Management
JANX icon

DnB Asset Management’s Janux Therapeutics JANX Stock Holding History

DnB Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,274
Closed -$238K – 1247
2025
Q4 		$238K Buy
17,274
+8,355
+94% +$197K ﹤0.01% 707
2025
Q3 		$218K Sell
8,919
-334
-4% -$8.13K ﹤0.01% 709
2025
Q2 		$214K Buy
9,253
+1,488
+19% +$39.2K ﹤0.01% 694
2025
Q1 		$210K Buy
7,765
+1,987
+34% +$74.9K ﹤0.01% 705
2024
Q4 		$309K Sell
5,778
-475
-8% -$25.1K ﹤0.01% 685
2024
Q3 		$284K Buy
6,253
+980
+19% +$42.6K ﹤0.01% 681
2024
Q2 		$221K Buy
+5,273
New +$248K ﹤0.01% 692

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DnB Asset Management's JANX Position: Q1 2026 in Review

DnB Asset Management sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 17,274 shares — an estimated $238K sold.

DnB Asset Management first reported a position in JANX in Q2 2024 and held it in 7 quarters. The position peaked at $309K in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • DnB Asset Management reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DnB Asset Management sold 17,274 Janux Therapeutics shares in Q1 2026, an estimated $238K.
  • DnB Asset Management first reported a position in Janux Therapeutics in Q2 2024 and held it in 7 quarters.
  • DnB Asset Management's Janux Therapeutics position peaked at $309K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.